Order Article Reprints

Fedele P, Stucci SL, Landriscina M, Morritti M, Giuliani F, Moraca L, Cairo G, Ardito R, Giampaglia M, Bilancia D, et al. Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Cancers. 2025; 17(21):3554. https://doi.org/10.3390/cancers17213554

Fedele, Palma, Stefania Luigia Stucci, Matteo Landriscina, Maria Morritti, Francesco Giuliani, Lucia Moraca, Giuseppe Cairo, Raffaele Ardito, Marianna Giampaglia, Domenico Bilancia, and et al. 2025. "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis" Cancers 17, no. 21: 3554. https://doi.org/10.3390/cancers17213554

Fedele, P., Stucci, S. L., Landriscina, M., Morritti, M., Giuliani, F., Moraca, L., Cairo, G., Ardito, R., Giampaglia, M., Bilancia, D., Melaccio, A., Terenzio, A., Gnoni, A., Licchetta, A., Fumai, F., Lanotte, L., Rizzo, A., & Gadaleta-Caldarola, G. (2025). Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Cancers, 17(21), 3554. https://doi.org/10.3390/cancers17213554